Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

• Published in: Clinical pharmacokinetics Vol. 56; no. 11; pp. 1381 - 1390
• Main Authors: Marbury, Thomas C., Flint, Anne, Jacobsen, Jacob B., Derving Karsbøl, Julie, Lasseter, Kenneth
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2017; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Angina pectoris; Antidiabetics; Blood pressure; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Drug dosages; Female; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - blood; Glucagon-Like Peptides - pharmacokinetics; Hemodialysis; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Internal Medicine; Kidney diseases; Male; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Original; Original Research Article; Patients; Peptides; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Renal Insufficiency - blood; Renal Insufficiency - complications; Young Adult; Moderate Renal Impairment; Normal Renal Function; Severe Renal Impairment; Renal Impairment; Liraglutide

Background The pharmacokinetics and tolerability of semaglutide, a once-weekly human glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus, were investigated in subjects with/without renal impairment (RI). Methods Fifty-six subjects, categorized into renal funct...